Clinical trials in Corbeil Essonnes – page 27

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Corbeil Essonnes at a glance

3 332

clinical trials

Research sites1

Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Interstitial lung disease+1

Recruiting

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Liquidia Technologies Inc.

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

France

Participants:18–64 years · 65+ years
Substances:ABBV-142
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Mantle cell lymphoma recurrent+1

Recruiting

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Lichen planus

Recruiting

A study of upadacitinib in adults with erosive mucosal lichen planus and lichen planopilaris.

Registered drug

A study of upadacitinib in adults with erosive mucosal lichen planus and lichen planopilaris.

Registered drug

France

Participants:18–64 years
Substances:Upadacitinib
Sponsor:Centre Hospitalier Universitaire De Nice

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Janssen Cilag International

Contact Research Centre

Thrombotic thrombocytopenic purpura+1

Recruiting

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Urokinase, catalytic domain, fused with a single-chain antibody against VON willebrand factor
Sponsor:TargED Biopharmaceuticals B.V.

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Peripheral arterial occlusive disease+5

Recruiting

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Clopidogrel
Sponsor:Fondation Hopital Saint Joseph

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Novartis Pharma AG

Contact Research Centre

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

France

Participants:18–64 years · 65+ years
Substances:SAR445399
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational

France

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Nerandomilast
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

Glycemic Control Studies
Cardiovascular Risk Management
Weight Management Therapies

02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

Novel Drug Combinations
Maintenance Therapy Optimization
Minimal Residual Disease Studies

03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

Immunotherapy Development
Alternative Treatment Strategies
Disease Management Protocols

Back to France All countries